Literature DB >> 15380148

Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome.

Fleur R Cattrall1, David L Healy.   

Abstract

Metabolic abnormalities and obesity have long been associated with the development of cardiovascular disease in the general population. These same features are also associated with polycystic ovary syndrome (PCOS). An increased prevalence of hypertension, dyslipidaemia, obesity and hyperinsulinaemia, as well as changes in coagulation and blood vessel function, provide an explanation as to why women with PCOS are at an increased risk of developing cardiovascular disease over the long term.

Entities:  

Mesh:

Year:  2004        PMID: 15380148     DOI: 10.1016/j.bpobgyn.2004.05.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  9 in total

Review 1.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.

Authors:  Jean-Patrice Baillargeon; Maria J Iuorno; Teimuraz Apridonidze; John E Nestler
Journal:  Metab Syndr Relat Disord       Date:  2010-04       Impact factor: 1.894

3.  Impact of obesity on the risk for polycystic ovary syndrome.

Authors:  Bulent O Yildiz; Eric S Knochenhauer; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2007-10-09       Impact factor: 5.958

4.  Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action.

Authors:  Vanita Aroda; Theodore P Ciaraldi; Sang-Ah Chang; Michael H Dahan; R Jeffrey Chang; Robert R Henry
Journal:  Fertil Steril       Date:  2007-08-13       Impact factor: 7.329

5.  Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism.

Authors:  Jean-Patrice Baillargeon; John E Nestler; Richard E Ostlund; Teimuraz Apridonidze; Evanthia Diamanti-Kandarakis
Journal:  Hum Reprod       Date:  2008-03-29       Impact factor: 6.918

6.  Rats with steroid-induced polycystic ovaries develop hypertension and increased sympathetic nervous system activity.

Authors:  Elisabet Stener-Victorin; Karolina Ploj; Britt-Mari Larsson; Agneta Holmäng
Journal:  Reprod Biol Endocrinol       Date:  2005-09-07       Impact factor: 5.211

7.  Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials.

Authors:  Vittorio Unfer; Fabio Facchinetti; Beatrice Orrù; Barbara Giordani; John Nestler
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335

8.  Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people.

Authors:  Virginia P Quinn; Rebecca Nash; Enid Hunkeler; Richard Contreras; Lee Cromwell; Tracy A Becerra-Culqui; Darios Getahun; Shawn Giammattei; Timothy L Lash; Andrea Millman; Brandi Robinson; Douglas Roblin; Michael J Silverberg; Jennifer Slovis; Vin Tangpricha; Dennis Tolsma; Cadence Valentine; Kevin Ward; Savannah Winter; Michael Goodman
Journal:  BMJ Open       Date:  2017-12-27       Impact factor: 2.692

9.  Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study.

Authors:  Mojca Jensterle; Katja Goricar; Andrej Janez
Journal:  Exp Ther Med       Date:  2016-02-16       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.